First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 577-583

  Saito, Kaku ^a   Nagashima, Hirotaka ^b   Noguchi, Kazuharu ^a   Yoshisue, Kunihiro ^a   Yokogawa, Tatsushi ^a   Matsushima, Eiji ^a   Tahara, Takeshi ^a   Takagi, Shigeru ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b Life Extension Research Institute Foundation   (Japan)

Author keywords

5 Fluorouracil; CYP3A4; DPD; dUTPase; First in human study; PK; Safety

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; C REACTIVE PROTEIN; CAPECITABINE; CYTOCHROME P450 3A4; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HYDROCORTISONE; HYDROLASE INHIBITOR; PLACEBO; TAS 114; UNCLASSIFIED DRUG; UROBILINOGEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; LEUKOCYTOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; NORMAL HUMAN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HEALTHY VOLUNTEERS; HUMANS; MALE; PYROPHOSPHATASES; YOUNG ADULT;

EID: 84896038197     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2383-2     Document Type: Article

References (21)

1. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R et al (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179:663-666
2. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338 (Pubitemid 37328853)
3. Aherne GW, Browne S. The role of uracil misincorporation in thymineless death, in anticancer drug development guide: antifolate drugs in cancer therapy. Jackman AL (ed) Humana Press Inc., Totowa, p 409-421
4. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC et al (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647 (Pubitemid 24379651)
5. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV et al (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412
6. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H et al (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182 (Pubitemid 26020011)
7. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM (1994) Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12:2035-2042 (Pubitemid 24356018)
8. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C et al (1999) Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17:1760-1770 (Pubitemid 29269245)
9. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y et al (2004) Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91:1245-1250 (Pubitemid 39424782)
10. Canman CE, Radany EH, Parsels LA, Davis MA, Lawrence TS, Maybaum J (1994) Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichia coli deoxyuridinetriphosphatase. Cancer Res 54:2296-2298 (Pubitemid 24138711)
11. Koehler SE, Ladner RD (2004) Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition. Mol Pharmacol 66:620-626 (Pubitemid 39329261)
12. Ladner RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ et al (2000) dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res 60:3493-3503 (Pubitemid 30482169)
13. Adlard JW, Richman SD, Royston P, Allan JM, Meade A, Parmar M et al (2004). Assessment of multiple markers for association with response rate (RR) and failure-free survival (FFS) in patients with advanced colorectal cancer (CRC) treated with chemotherapy in the MRC CR08 (FOCUS) randomized trial. J Clin Oncol ASCO Annual meeting proceedings (post-meeting edition). Vol 22: Abstract no. 9506
14. Richman S, Braun MS, Adlard JW, Daly C, Turner F, Barrett J et al (2006) Prognostic value of thymidylate synthase (TS) expression on failure-free survival of fluorouracil-treated metastatic colorectal cancer patients. J Clin Oncol ASCO Annual meeting proceedings part I. Vol 24 (June 20 Supplement): Abstract no. 10011
15. Nobili S, Napoli C, Landini I, Morganti M, Cianchi F, Valanzano R et al (2011) Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int J Cancer 128:1935-1945
16. Yano W, Yokogawa T, Fukuoka M, Miyakoshi H, Miyahara S, Ueno H et al (2012) In vitro characterization of a novel dUTPase inhibitor, TAS-114, as a fluoropyrimidine enhancer. Eur J Cancer 48(Suppl 6):22
17. Yokogawa T, Wakasa T, Yano W, Yoshisue K, Fujioka A, Eshima K et al (2012) TAS-114 enhances S-1 activity in vivo when used in combination. Eur J Cancer 48(Suppl 6):22
18. Wakasa T, Yamamura K, Tsuji S, Osada A, Matsushima E, Yokogawa T et al (2012) TAS-114 in combination, with capecitabine-based chemotherapy may represent a novel therapeutic strategy. Eur J Cancer 48(Suppl 6):22-23
19. Jiang H, Lu J, Ji J (2004) Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 141:616-623 (Pubitemid 38453253)
20. Galteau MM, Shamsa F (2003) Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713-733 (Pubitemid 38041296)
21. Yen-Revollo JL, Goldberg RM, McLeod HL (2008) Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 14:8-13 (Pubitemid 351377972)